300573 兴齐眼药
已收盘 11-19 15:00:00
资讯
新帖
简况
兴齐眼药：盐酸利多卡因眼用凝胶获临床试验批准
美港电讯 · 11-18 15:46
兴齐眼药：盐酸利多卡因眼用凝胶获临床试验批准
兴齐眼药(300573.SZ)：盐酸利多卡因眼用凝胶获临床试验批准
智通财经 · 11-18 15:46
兴齐眼药(300573.SZ)：盐酸利多卡因眼用凝胶获临床试验批准
兴齐眼药(300573.SZ)：环孢素滴眼液(Ⅱ)上市后临床试验取得Ⅳ期临床研究报告
智通财经 · 11-12
兴齐眼药(300573.SZ)：环孢素滴眼液(Ⅱ)上市后临床试验取得Ⅳ期临床研究报告
兴齐眼药(300573.SZ)：盐酸奥洛他定滴眼液获药品注册证书
智通财经 · 11-11
兴齐眼药(300573.SZ)：盐酸奥洛他定滴眼液获药品注册证书
兴齐眼药（300573）82.44万股限售股将于11月11日解禁，占总股本0.47%
证券之星 · 11-11
兴齐眼药（300573）82.44万股限售股将于11月11日解禁，占总股本0.47%
开源证券：给予兴齐眼药买入评级
证券之星 · 11-04
开源证券：给予兴齐眼药买入评级
11月4日兴齐眼药涨7.05%，富国天博创新主题混合基金重仓该股
证券之星 · 11-04
11月4日兴齐眼药涨7.05%，富国天博创新主题混合基金重仓该股
兴齐眼药：11月1日接受机构调研，包括知名机构正心谷资本的多家机构参与
证券之星 · 11-02
兴齐眼药：11月1日接受机构调研，包括知名机构正心谷资本的多家机构参与
兴齐眼药最新公告：撤回马来酸噻吗洛尔滴眼液注册申请
证券之星 · 10-30
兴齐眼药最新公告：撤回马来酸噻吗洛尔滴眼液注册申请
兴齐眼药（300573）10月29日主力资金净卖出3.31亿元
证券之星 · 10-30
兴齐眼药（300573）10月29日主力资金净卖出3.31亿元
兴齐眼药（300573）2024年三季报简析：营收净利润同比双双增长，三费占比上升明显
证券之星 · 10-30
兴齐眼药（300573）2024年三季报简析：营收净利润同比双双增长，三费占比上升明显
10月29日兴齐眼药跌8.42%，富国天博创新主题混合基金重仓该股
证券之星 · 10-29
10月29日兴齐眼药跌8.42%，富国天博创新主题混合基金重仓该股
图解兴齐眼药三季报：第三季度单季净利润同比增28.41%
证券之星 · 10-28
图解兴齐眼药三季报：第三季度单季净利润同比增28.41%
兴齐眼药(300573.SZ)发布前三季度业绩，净利润2.91亿元，增长59.47%
智通财经 · 10-28
兴齐眼药(300573.SZ)发布前三季度业绩，净利润2.91亿元，增长59.47%
兴齐眼药（300573）10月22日主力资金净买入2.40亿元
证券之星 · 10-23
兴齐眼药（300573）10月22日主力资金净买入2.40亿元
兴齐眼药最新公告：撤回盐酸丙美卡因滴眼液的注册申请
证券之星 · 10-22
兴齐眼药最新公告：撤回盐酸丙美卡因滴眼液的注册申请
兴齐眼药(300573.SZ)撤回盐酸丙美卡因滴眼液注册申请获同意
智通财经 · 10-22
兴齐眼药(300573.SZ)撤回盐酸丙美卡因滴眼液注册申请获同意
10月22日兴齐眼药涨9.18%，富国天惠LOF基金重仓该股
证券之星 · 10-22
10月22日兴齐眼药涨9.18%，富国天惠LOF基金重仓该股
兴齐眼药(300573.SZ)取得硫酸阿托品滴眼液(0.02%0.04%)Ⅲ期临床试验总结报告
智通财经 · 10-21
兴齐眼药(300573.SZ)取得硫酸阿托品滴眼液(0.02%0.04%)Ⅲ期临床试验总结报告
10月18日兴齐眼药涨6.18%，富国天惠LOF基金重仓该股
证券之星 · 10-18
10月18日兴齐眼药涨6.18%，富国天惠LOF基金重仓该股
暂无数据
公司概况
公司名称：
沈阳兴齐眼药股份有限公司
所属行业：
医药制造业
上市日期：
2016-12-08
主营业务：
沈阳兴齐眼药股份有限公司专注于眼科药物领域,是一家主要从事眼科药物研发、生产、销售的专业企业,主要产品是眼科处方药物。以“兹润”、“速高捷”、“迪友”、“迪非”、“兹养”等产品为代表的眼用制剂产品已在行业内树立了良好的品牌声誉。公司多项产品被认定为国家重点新产品、省名牌产品、省优秀新产品、省质量名优产品。
发行价格：
5.16
{"stockData":{"symbol":"300573","market":"SZ","secType":"STK","nameCN":"兴齐眼药","latestPrice":85.78,"timestamp":1731999795000,"preClose":84.25,"halted":0,"volume":6446380,"delay":0,"floatShares":135000000,"shares":175000000,"eps":1.9885,"marketStatus":"已收盘","marketStatusCode":5,"change":1.53,"latestTime":"11-19 15:00:00","open":84.99,"high":86.4,"low":83,"amount":545000000,"amplitude":0.0404,"askPrice":85.79,"askSize":66,"bidPrice":85.78,"bidSize":46,"shortable":0,"etf":0,"ttmEps":1.9885,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732066200000},"adr":0,"adjPreClose":84.25,"symbolType":"stock","openAndCloseTimeList":[[1731979800000,1731987000000],[1731992400000,1731999600000]],"highLimit":92.68,"lowLimit":75.83,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":175249247,"pbRate":9.07,"roa":"--","roe":"16.03%","epsLYR":1.93,"committee":0.192308,"marketValue":15033000000,"floatMarketCap":11564000000,"peRate":43.138044,"changeRate":0.0182,"turnoverRate":0.0478,"status":0},"requestUrl":"/m/hq/s/300573/tweets","defaultTab":"tweets","newsList":[{"id":"2484552614","title":"兴齐眼药：盐酸利多卡因眼用凝胶获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484552614","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484552614?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:46","pubTimestamp":1731916010,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1583","300573","03347","BK1576","BK0239","BK0177","BK1141"],"gpt_icon":0},{"id":"2484614919","title":"兴齐眼药(300573.SZ)：盐酸利多卡因眼用凝胶获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2484614919","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484614919?lang=zh_cn&edition=full","pubTime":"2024-11-18 15:46","pubTimestamp":1731916004,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)公告，公司收到国家药品监督管理局签发的关于盐酸利多卡因眼用凝胶的《药物临床试验批准通知书》，盐酸利多卡因眼用凝胶适应症为适用于眼科操作中的眼表麻醉。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300573","BK1576","BK0239","BK0177","BK1141","03347","BK1583"],"gpt_icon":0},{"id":"2482268927","title":"兴齐眼药(300573.SZ)：环孢素滴眼液(Ⅱ)上市后临床试验取得Ⅳ期临床研究报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2482268927","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482268927?lang=zh_cn&edition=full","pubTime":"2024-11-12 15:44","pubTimestamp":1731397454,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药 发布公告，公司的产品环孢素滴眼液(Ⅱ)，近期获得了“环孢素滴眼液(Ⅱ)治疗干眼的安全性和有效性多中心临床研究”的Ⅳ期临床研究报告。该研究是一项多中心、前瞻性临床试验，1999例受试者经过了为期24周的用药观察，评价环孢素滴眼液(Ⅱ)用于干眼患者的安全性和有效性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1576","03347","BK0239","BK1141","BK0177","300573"],"gpt_icon":0},{"id":"2482270522","title":"兴齐眼药(300573.SZ)：盐酸奥洛他定滴眼液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482270522","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482270522?lang=zh_cn&edition=full","pubTime":"2024-11-11 17:14","pubTimestamp":1731316440,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)公告，公司收到国家药品监督管理局核准签发的盐酸奥洛他定滴眼液《药品注册证书》。公司本次获批的盐酸奥洛他定滴眼液为多剂量产品，临床适应症为用于治疗过敏性结膜炎相关的眼痒。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0177","BK0239","300573"],"gpt_icon":0},{"id":"2482219405","title":"兴齐眼药（300573）82.44万股限售股将于11月11日解禁，占总股本0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482219405","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482219405?lang=zh_cn&edition=full","pubTime":"2024-11-11 08:02","pubTimestamp":1731283372,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，兴齐眼药于11月11日将有82.44万股限售股份解禁，为公司股权激励一般股份，占公司总股本0.47%。本次解禁后，公司还有4043.6万股限售股份，占总股本23.18%。兴齐眼药主营业务：眼科药物研发、生产、销售的专业企业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111100001076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2480586603","title":"开源证券：给予兴齐眼药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2480586603","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480586603?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:10","pubTimestamp":1730729438,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,刘艺近期对兴齐眼药进行研究并发布了研究报告《公司信息更新报告：静待低浓度阿托品加速放量，眼科产品持续完善》，本报告对兴齐眼药给出买入评级，当前股价为89.49元。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为180.23。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400031683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300573"],"gpt_icon":0},{"id":"2480373234","title":"11月4日兴齐眼药涨7.05%，富国天博创新主题混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480373234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480373234?lang=zh_cn&edition=full","pubTime":"2024-11-04 16:21","pubTimestamp":1730708518,"startTime":"0","endTime":"0","summary":"证券之星消息，11月4日兴齐眼药涨7.05%，收盘报89.49元，换手率8.74%，成交量11.72万手，成交额10.3亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共35家，其中持有数量最多的公募基金为富国天博创新主题混合。富国天博创新主题混合目前规模为18.35亿元，最新净值1.6842，较上一交易日下跌0.49%，近一年下跌4.89%。富国天博创新主题混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400020222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2480841960","title":"兴齐眼药：11月1日接受机构调研，包括知名机构正心谷资本的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2480841960","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480841960?lang=zh_cn&edition=full","pubTime":"2024-11-02 17:31","pubTimestamp":1730539876,"startTime":"0","endTime":"0","summary":"答：公司 0.01%低浓度硫酸阿托品滴眼液上市后，根据我们当时的查询结果，共有 9 家医疗机构获得医疗机构制剂批件。截至目前，上述医疗机构制剂批件还剩余 6家，其中有 3家适应症为散瞳和睫状肌麻痹，而且这些医疗机构制剂仅限在本医疗机构范围内使用，受众人群有限。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110200006953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2479222541","title":"兴齐眼药最新公告：撤回马来酸噻吗洛尔滴眼液注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2479222541","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479222541?lang=zh_cn&edition=full","pubTime":"2024-10-30 16:51","pubTimestamp":1730278297,"startTime":"0","endTime":"0","summary":"兴齐眼药公告，公司收到国家药监局核准签发的《药品注册申请终止通知书》，同意公司撤回马来酸噻吗洛尔滴眼液的注册申请。公司于2023年3月递交该药品仿制药上市注册申请并获受理，因政策法规变更等因素影响，需进一步完善申报资料，经审慎研究，公司决定主动撤回本次补充申请。该药品注册申请的主动撤回并终止对已上市产品及公司研发工作无重大影响。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000029626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2479291865","title":"兴齐眼药（300573）10月29日主力资金净卖出3.31亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479291865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479291865?lang=zh_cn&edition=full","pubTime":"2024-10-30 09:17","pubTimestamp":1730251057,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月29日收盘，兴齐眼药报收于89.31元，下跌8.42%，换手率14.22%，成交量19.06万手，成交额17.42亿元。10月29日的资金流向数据方面，主力资金净流出3.31亿元，占总成交额19.01%，游资资金净流入1.09亿元，占总成交额6.24%，散户资金净流入2.23亿元，占总成交额12.78%。融券方面，融券卖出2000.0股，融券偿还300.0股，融券余量6.28万股，融券余额561.01万元。兴齐眼药主营业务：眼科药物研发、生产、销售的专业企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000010331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2479261313","title":"兴齐眼药（300573）2024年三季报简析：营收净利润同比双双增长，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2479261313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479261313?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:30","pubTimestamp":1730241025,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期兴齐眼药发布2024年三季报。截至本报告期末，公司营业总收入14.39亿元，同比上升30.27%，归母净利润2.91亿元，同比上升59.47%。按单季度数据看，第三季度营业总收入5.47亿元，同比上升30.54%，第三季度归母净利润1.21亿元，同比上升28.41%。本报告期兴齐眼药三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达33.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000006676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573"],"gpt_icon":0},{"id":"2479005429","title":"10月29日兴齐眼药跌8.42%，富国天博创新主题混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2479005429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479005429?lang=zh_cn&edition=full","pubTime":"2024-10-29 16:21","pubTimestamp":1730190098,"startTime":"0","endTime":"0","summary":"证券之星消息，10月29日兴齐眼药跌8.42%，收盘报89.31元，换手率14.22%，成交量19.06万手，成交额17.42亿元。根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共35家，其中持有数量最多的公募基金为富国天博创新主题混合。富国天博创新主题混合目前规模为18.35亿元，最新净值1.7308，较上一交易日下跌0.59%，近一年下跌2.0%。富国天博创新主题混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900027595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0177","BK0239"],"gpt_icon":0},{"id":"2478617192","title":"图解兴齐眼药三季报：第三季度单季净利润同比增28.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478617192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478617192?lang=zh_cn&edition=full","pubTime":"2024-10-28 17:20","pubTimestamp":1730107208,"startTime":"0","endTime":"0","summary":"证券之星消息，兴齐眼药2024年三季报显示，公司主营收入14.39亿元，同比上升30.27%；归母净利润2.91亿元，同比上升59.47%；扣非净利润2.9亿元，同比上升63.31%；其中2024年第三季度，公司单季度主营收入5.47亿元，同比上升30.54%；单季度归母净利润1.21亿元，同比上升28.41%；单季度扣非净利润1.21亿元，同比上升32.18%；负债率25.53%，投资收益-2.42万元，财务费用-15.56万元，毛利率78.38%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800023437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573"],"gpt_icon":0},{"id":"2478739671","title":"兴齐眼药(300573.SZ)发布前三季度业绩，净利润2.91亿元，增长59.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478739671","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478739671?lang=zh_cn&edition=full","pubTime":"2024-10-28 16:29","pubTimestamp":1730104141,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布2024年三季度报告，该公司前三季度营业收入为14.39亿元，同比增长30.27%。归属于上市公司股东的净利润为2.91亿元，同比增长59.47%。归属于上市公司股东的扣除非经常性损益的净利润为2.9亿元，同比增长63.31%。基本每股收益为1.67元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300573"],"gpt_icon":0},{"id":"2477127473","title":"兴齐眼药（300573）10月22日主力资金净买入2.40亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477127473","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477127473?lang=zh_cn&edition=full","pubTime":"2024-10-23 09:12","pubTimestamp":1729645962,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年10月22日收盘，兴齐眼药报收于101.52元，上涨9.18%，换手率13.5%，成交量18.08万手，成交额17.75亿元。10月22日的资金流向数据方面，主力资金净流入2.4亿元，占总成交额13.54%，游资资金净流出701.86万元，占总成交额0.4%，散户资金净流出2.33亿元，占总成交额13.14%。融券方面，融券卖出2100.0股，融券偿还3800.0股，融券余量5.15万股，融券余额522.99万元。兴齐眼药主营业务：眼科药物研发、生产、销售的专业企业。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300008329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2477274802","title":"兴齐眼药最新公告：撤回盐酸丙美卡因滴眼液的注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2477274802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477274802?lang=zh_cn&edition=full","pubTime":"2024-10-22 16:49","pubTimestamp":1729586962,"startTime":"0","endTime":"0","summary":"兴齐眼药公告，近日，公司收到国家药监局核准签发的《药品注册申请终止通知书》，同意公司撤回盐酸丙美卡因滴眼液的注册申请。公司于2023年12月向国家药监局递交盐酸丙美卡因滴眼液仿制药上市注册申请并获受理，申报适应症为：用于眼科局部麻醉。受政策法规变更等因素影响，结合市场注册申报情况及公司研发策略，经审慎研究，公司决定主动撤回该注册申请。该药品注册申请的主动撤回并终止对公司研发工作无重大影响，也不会对公司当期及未来生产经营与业绩产生重大影响。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200025768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2477010318","title":"兴齐眼药(300573.SZ)撤回盐酸丙美卡因滴眼液注册申请获同意","url":"https://stock-news.laohu8.com/highlight/detail?id=2477010318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477010318?lang=zh_cn&edition=full","pubTime":"2024-10-22 16:22","pubTimestamp":1729585337,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)公告，公司收到国家药品监督管理局核准签发的《药品注册申请终止通知书》，同意公司撤回盐酸丙美卡因滴眼液的注册申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1197333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2477801228","title":"10月22日兴齐眼药涨9.18%，富国天惠LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2477801228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477801228?lang=zh_cn&edition=full","pubTime":"2024-10-22 16:18","pubTimestamp":1729585120,"startTime":"0","endTime":"0","summary":"证券之星消息，10月22日兴齐眼药涨9.18%，收盘报101.52元，换手率13.5%，成交量18.08万手，成交额17.75亿元。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共66家，其中持有数量最多的公募基金为富国天惠LOF。富国天惠LOF目前规模为251.85亿元，最新净值2.4602，较上一交易日上涨0.21%，近一年上涨2.47%。富国天惠LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200024561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177","161005"],"gpt_icon":0},{"id":"2477833949","title":"兴齐眼药(300573.SZ)取得硫酸阿托品滴眼液(0.02%0.04%)Ⅲ期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2477833949","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477833949?lang=zh_cn&edition=full","pubTime":"2024-10-21 16:31","pubTimestamp":1729499492,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)公告，公司近日获得了“不同浓度硫酸阿托品滴眼液(0.02%/0.04%)延缓儿童近视进展的有效性和安全性的随机、双盲、安慰剂平行对照、多中心III期临床试验”临床总结报告。该项研究是一项随机、双盲、安慰剂平行对照、多中心临床试验，800例6-12岁儿童受试者经过了为期2年的用药观察，评估0.02%、0.04%硫酸阿托品滴眼液延缓儿童近视进展的有效性和安全性。研究结果显示，0.02%、0.04%硫酸阿托品滴眼液组对比安慰剂组在主要疗效指标上有统计学意义的显著性差异，硫酸阿托品滴眼液组优于安慰剂组，安全性良好，患者使用依从性好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1196716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK0239","03347","300573","BK0177","BK1576","BK1583"],"gpt_icon":0},{"id":"2476470898","title":"10月18日兴齐眼药涨6.18%，富国天惠LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2476470898","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476470898?lang=zh_cn&edition=full","pubTime":"2024-10-18 16:32","pubTimestamp":1729240371,"startTime":"0","endTime":"0","summary":"证券之星消息，10月18日兴齐眼药涨6.18%，收盘报92.11元，换手率10.18%，成交量13.64万手，成交额12.39亿元。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共66家，其中持有数量最多的公募基金为富国天惠LOF。富国天惠LOF目前规模为251.85亿元，最新净值2.3757，较上一交易日下跌1.43%，近一年下跌5.16%。富国天惠LOF的前十大重仓股如下：以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101800026379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","161005","BK0177","300573"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2016-12-08","address":"辽宁省沈阳市浑南区中国(辽宁)自由贸易试验区沈阳片区新运河路25号","stockEarnings":[{"period":"1week","weight":-0.1016},{"period":"1month","weight":-0.0853},{"period":"3month","weight":-0.1467},{"period":"6month","weight":-0.5661},{"period":"1year","weight":-0.208},{"period":"ytd","weight":-0.3423}],"companyName":"沈阳兴齐眼药股份有限公司","boardCode":"AI0027","perCapita":"3496股","boardName":"医药制造业","registeredCapital":"17524万元","compareEarnings":[{"period":"1week","weight":-0.0421},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.0523},{"period":"1year","weight":0.0882},{"period":"ytd","weight":0.1173}],"survey":" 沈阳兴齐眼药股份有限公司专注于眼科药物领域,是一家主要从事眼科药物研发、生产、销售的专业企业,主要产品是眼科处方药物。以“兹润”、“速高捷”、“迪友”、“迪非”、“兹养”等产品为代表的眼用制剂产品已在行业内树立了良好的品牌声誉。公司多项产品被认定为国家重点新产品、省名牌产品、省优秀新产品、省质量名优产品。","serverTime":1732005594303,"listedPrice":5.16,"stockholders":"38554人(较上一季度增加108.98%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"兴齐眼药,300573,兴齐眼药股票,兴齐眼药股票老虎,兴齐眼药股票老虎国际,兴齐眼药行情,兴齐眼药股票行情,兴齐眼药股价,兴齐眼药股市,兴齐眼药股票价格,兴齐眼药股票交易,兴齐眼药股票购买,兴齐眼药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}